AFMDQ (Affimed NV) EPS (Diluted): $-4.98 (TTM As of Sep. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AFMDQ Affimed NV AFMDQ
16 GF Score
Price $0.00
View Full Analysis

What is Affimed NV EPS (Diluted)?

Affimed NV AFMDQ 16 EPS (Diluted) is $-4.98 as of Sep. 2024. GuruFocus rates AFMDQ with a GF Score™ of 16/100.

Affimed NV's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-1.04. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.98.

Affimed NV's EPS (Basic) for the three months ended in Sep. 2024 was $-1.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.98.

Affimed NV's EPS without NRI for the three months ended in Sep. 2024 was $-1.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was $-5.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Affimed NV  (OTCPK:AFMDQ) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Affimed NV EPS (Diluted) Related Terms

Affimed NV EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for Affimed NV's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Affimed NV EPS (Diluted) Chart

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.56 -6.08 -5.44 -6.40 -7.73

Affimed NV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 -1.47 -1.38 -1.09 -1.04

AFMDQ vs SYRS, BTAX, TRVN: EPS (Diluted) Comparison

For the Biotechnology subindustry, Affimed NV's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's PE Ratio distribution charts can be found below:

* The bar in red indicates where Affimed NV's PE Ratio falls into.


AFMDQ
16GF Score
Affimed NV AFMDQ
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Affimed NV EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Affimed NV's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-115.527-0)/14.940
=-7.73

Affimed NV's Diluted EPS for the quarter that ended in Sep. 2024 is calculated as

Diluted EPS (Q: Sep. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-16.802-0)/16.100
=-1.04

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of $-4.98 mean?
Affimed NV (AFMDQ) has a EPS (Diluted) of $-4.98 as of Sep. 2024. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Affimed NV and its competitors.
Is Affimed NV's EPS (Diluted) too high?
Affimed NV's current EPS (Diluted) is $-4.98. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's EPS (Diluted) compare to SYRS and BTAX?
Affimed NV's EPS (Diluted) of $-4.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Affimed NV and its competitors. Affimed NV's current EPS (Diluted) is $-4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current EPS (Diluted) of $-4.98. The current EPS (Diluted) is $-4.98. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current EPS (Diluted) is $-4.98 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Affimed NV Business Description

Address Gottlieb-Daimler-Strabe 2, Mannheim, BW, DEU, 68165
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score

Get the complete analysis for AFMDQ

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price